Literature DB >> 15752239

Genetic factors in end-stage renal disease.

Scott G Satko1, Barry I Freedman, Shahriar Moossavi.   

Abstract

Despite more aggressive treatment of diabetes, hypertension, and hyperlipidemia, the incidence and prevalence rates of end-stage renal disease (ESRD) continue to increase worldwide. The likelihood of developing chronic kidney disease in an individual is determined by interactions between genes and the environment. Familial clustering of nephropathy has repeatedly been observed in all population groups studied and for multiple etiologies of kidney disease. A three- to nine-fold greater risk of ESRD is observed in individuals with a family history of ESRD. Marked racial variation in the familial aggregation of kidney disease exists, with high rates in African American, Native American, and Hispanic American families. Disparate etiologies of nephropathy aggregate within African American families, as well. These data have led several investigators to search for genes linked to diabetic and other forms of nephropathy. Evidence for linkage to kidney disease has been detected and replicated at several loci on chromosomes 3q (types 1 and 2 diabetic nephropathy), 10q (diabetic and nondiabetic kidney disease), and 18q (type 2 diabetic nephropathy). Multicenter consortia are currently recruiting large numbers of multiplex diabetic families with index cases having nephropathy for linkage and association analyses. In addition, large-scale screening studies are underway, with the goals of better defining the overall prevalence of chronic kidney disease, as well as educating the population about risk factors for nephropathy, including family history. Given the overwhelming burden of kidney disease worldwide, it is imperative that we develop a clearer understanding of the pathogenesis of nephropathy so that individuals at risk can be identified and treated at earlier, potentially reversible, stages of their illness.

Entities:  

Mesh:

Year:  2005        PMID: 15752239     DOI: 10.1111/j.1523-1755.2005.09411.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  24 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  A lesson from the Zuni Indians: heritability in perspective.

Authors:  Madhumathi Rao; Inga Peter; Thomas A Trikalinos
Journal:  Am J Kidney Dis       Date:  2010-08       Impact factor: 8.860

Review 3.  Role of cytogenetic biomarkers in management of chronic kidney disease patients: A review.

Authors:  Zeba Khan; Manoj Pandey; Ravindra M Samartha
Journal:  Int J Health Sci (Qassim)       Date:  2016-10

Review 4.  Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.

Authors:  Giuseppe Remuzzi; Ariela Benigni; Andrea Remuzzi
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

5.  Higher protein intake is associated with increased risk for incident end-stage renal disease among blacks with diabetes in the Southern Community Cohort Study.

Authors:  R Malhotra; K L Cavanaugh; W J Blot; T A Ikizler; L Lipworth; E K Kabagambe
Journal:  Nutr Metab Cardiovasc Dis       Date:  2016-07-21       Impact factor: 4.222

6.  Association of a CYP4A11 variant and blood pressure in black men.

Authors:  James V Gainer; Michael S Lipkowitz; Chang Yu; Michael R Waterman; Elliott P Dawson; Jorge H Capdevila; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

7.  Genetic contribution and associated pathophysiology in end-stage renal disease.

Authors:  Suraksha Agrawal; Ss Agarwal; Sita Naik
Journal:  Appl Clin Genet       Date:  2010-08-05

8.  Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment.

Authors:  Jinglan Zhang; Anastasia Fedick; Stephanie Wasserman; Geping Zhao; Lisa Edelmann; Erwin P Bottinger; Ruth Kornreich; Stuart A Scott
Journal:  J Mol Diagn       Date:  2016-01-07       Impact factor: 5.568

9.  Living Kidney Donors Who Develop Kidney Failure: Excerpts of Their Thoughts.

Authors:  Colin M E Halverson; Jackie Y Wang; Michael Poulson; Jennifer Karlin; Megan Crowley-Matoka; Lainie F Ross
Journal:  Am J Nephrol       Date:  2016-05-25       Impact factor: 3.754

10.  Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease.

Authors:  David J Friedman; Matthew E Talbert; Donald W Bowden; Barry I Freedman; Yves Mukanya; Keiichi Enjyoji; Simon C Robson
Journal:  Diabetes       Date:  2008-12-18       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.